

JAN - 4 2000

510(K) SUMMARY OF SAFETY AND EFFECTIVENESS**Rebar™ Micro Catheter**

Prepared December 2, 1999

TRADE NAME:	Rebar™ Micro Catheter		
GENERIC NAME:	Infusion Catheter	CLASSIFICATION:	Class II
SUBMITTED BY:	Micro Therapeutics, Inc. 2 Goodyear Irvine, CA 92618	CONTACT:	Tom Daughters Regulatory Affairs (949) 837-3700
PREDICATE DEVICE	Micro Therapeutics, Inc. Easy Rider Micro Catheter, K974473		
DEVICE DESCRIPTION	The Rebar Micro Catheter is a single-lumen catheter designed to be introduced over a steerable guidewire into the distal vasculature. The proximal end of the catheter incorporates a standard luer adapter to facilitate the attachment of accessories. The catheter has a semi-rigid proximal shaft which tapers into the flexible distal shaft to facilitate the advancement of the catheter in the anatomy. The outer surface of the catheter has a lubricious hydrophilic coating. The catheter has a radiopaque marker at the distal end to facilitate fluoroscopic visualization. Select catheter models (.0165" lumen) have a secondary marker 3 cm proximal of the distal tip marker.		
INDICATIONS FOR USE	The Rebar Micro Catheter is intended for the controlled selective infusion of physician-specified therapeutic agents or contrast media into the vasculature of the peripheral and neuro anatomy.		
SAFETY AND PERFORMANCE TESTS	<p>Biocompatibility of the Rebar catheter was verified in accordance with ISO 10993-1, Biological Evaluation of Medical Devices. Test results confirmed biocompatibility of the Rebar catheter when tested as an external communicating, blood contact, short duration device (<24 hr).</p> <p>Performance testing of the Rebar catheter was conducted in accordance with ISO 10555 Sterile, single use intravascular catheters – Part 1. Verification tests included: dimensional verification; catheter tensile, burst and torque strength; flexibility, trackability, and coating integrity. Test results demonstrate that the device meets or exceeds the requirements of these standards and performs substantially equivalent to the predicate device.</p>		
SUMMARY OF SUBSTANTIAL EQUIVALENCE	The Rebar Micro Catheter is substantially equivalent to the predicate device in intended use and principle of operation.		



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

JAN - 4 2000

Mr. Tom Daughters
Regulatory Affairs
Micro Therapeutics, Inc.
2 Goodyear
Irvine, CA 92618

Re: K993672
Trade Name: RebarTM Micro Catheter
Regulatory Class: II
Product Code: KRA
Dated: December 2, 1999
Received: December 6, 1999

Dear Mr. Daughters:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Page 2 - Mr. Tom Daughters

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4586. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,

A handwritten signature in black ink, appearing to read "Celia M. Witten".

Celia M. Witten, Ph.D., M.D.
Acting Director
Division of Cardiovascular,
Respiratory and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

Indications for Use Statement

**510(k)
Number
(if known)**

K993672

Device Name

Rebar™ Micro Catheter

**Indications
for Use**

The Rebar Micro Catheter is intended for the controlled selective infusion of physician-specified therapeutic agents or contrast media into the vasculature of the peripheral and neuro anatomy.

PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE
IF NEEDED

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use X
(Per 21 CFR 801.109)

Over-The-Counter
Use _____

Christy M. Witter